- Gastroenterology Advisor

Delays in Cancer Surgery Due to COVID-19 Could Harm Survival

Modest delays in cancer surgery due to the COVID-19 pandemic could have a significant impact on survival.

Family History-Based Early Screen Could Identify More Cases of Young-Onset CRC

About one in four cases of colorectal cancer in patients aged 40 to 49 years meet family history-based criteria for early screening.

Gastric Intestinal Metaplasia: 2020 AGA Guidelines

By

Andy Kistler, MD, PharmD

The American Gastroenterological Association recently published new clinical practice guidelines on the management of gastric intestinal metaplasia.

Although the use of value pathways in oncology appeared to extend time to treatment failure, it did not appear to influence overall survival.

Value Pathways for Treatment Decisions in Gastric Cancer Had Little Impact on OS

By

Randi Hernandez

Although the use of value pathways in oncology appeared to extend time to treatment failure, it did not appear to influence overall survival.

In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.

PFS With Maintenance Therapy in Some Esophageal or Gastric Cancers May Be Linked to PD-L1 Level

By

Susan Moench, PhD, PA-C

In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.

Woman with stomach pain sitting on bench

Stomach Virus Strikes 170 Yosemite Visitors, Staff

About 170 visitors and employees at Yosemite National Park have been hit by gastrointestinal illness, park officials say.

Ayvakit Approval for GI Stromal Tumor With PDGFRAM Mutation

By

Brian Park, PharmD

The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

“Unexpected” CDH1 Variants Lead to Uncertainty

By

Christina Bennett, MS

Unexpectedly identifying a patient as a CDH1 carrier can lead to a “difficult conundrum” for clinicians and patients, highlighting the need for pretest counseling.

Incidence of Early-Onset Gastric Cancer Increasing in the US

The incidence of early-onset gastric cancer has been increasing in the United States, and it seems to be distinct clinically and genetically from late-onset gastric cancer.

Continuous PPI Use May Increase Risk for Acute Gastroenteritis

Continuous use of proton pump inhibitor (PPI) therapy is associated with an increased risk for acute gastroenteritis (AGE) during winter epidemic periods with peak circulation of enteric viruses.

New Emerging Viruses Causing Acute Gastroenteritis in Children With Hematopoietic Cell Transplant

By

Zahra Masoud

The epidemiology of acute gastroenteritis pathogens identified from pediatric patients who have undergone allogenic hematopoietic cell transplant may be changing.

EGID Without Eosinophilia: Elevated Mucosal Mast Cell Counts

By

Gastroenterology Advisor Contributing Writer

Patients with suspected eosinophilic gastrointestinal disease (EGID) in the stomach or duodenum had an increased number of mucosal mast cells with or without mucosal eosinophilia.

Disaggregation and Variability of Gastric Cancer Risk and Survival in Asian American Subgroups

By

Dibash Kumar Das, PhD

The researchers discovered significant differences and substantial heterogeneity in risk for GC among API subgroups. Substantial differences in all-cause survival among API subgroups were also observed.

Updated ESMO Recommendations for Hereditary Gastrointestinal Cancers

By

Gastroenterology Advisor Contributing Writer

Recommendations were developed and graded in accordance with the ESMO Clinical Practice Guidelines and subjected to an anonymous peer-review process.

H. Pylori Treatment May Reduce Gastric Cancer Incidence, Death

Reductions in gastric cancer mortality seen with H. pylori treatment, vitamin, garlic supplementation.

Allergy Development May Increase After Gastric Acid Inhibitor Use

Patients receiving gastric acid inhibitors have an increase in prescriptions of anti-allergic drugs.

T2DM Increases Gastric Cancer Risk After H. Pylori Eradication

Type 2 diabetes was linked to an increased risk for gastric cancer (adjusted hazard ratio, 1.73). Stratified statistical analysis demonstrated a significantly higher risk for gastric cardia cancer (adjusted hazard ratio, 3.40) and a significantly increased risk in those with suboptimal glycemic control (adjusted hazard ratio, 1.68).

Teplizumab Gets Breakthrough Status for Type 1 Diabetes Prevention

By

Steve Duffy

The FDA has granted Breakthrough Therapy designation to teplizumab (PRV-031; Provention Bio), for the prevention or delay of clinical T1D in those at risk of developing the disease.

Researchers found that, among men previously treated for lymphoma, the incidence of breast cancer is

The Utility of Endoscopic Techniques in the Diagnosis of Gastric Lymphoma

By